TY - JOUR
T1 - New Developments in Clinical Bacteriology Laboratories
AU - Patel, Robin
N1 - Funding Information:
Potential Competing Interests: Dr Patel receives grants from BioFire, Check-Points, Curetis, 3M, Merck, Hutchison Biofilm Medical Solutions, Accelerate Diagnostics, Allergan, and The Medicines Company. She is a consultant to Curetis, Roche, Qvella, and Diaxonhit; monies are paid to Mayo Clinic. In addition, she has a patent on Bordetella pertussis/parapertussis polymerase chain reaction issued, a patent on a device/method for sonication issued, with royalties paid by Samsung to Mayo Clinic, and a patent on an antibiofilm substance issued. She serves on an Actelion data monitoring board. She receives travel reimbursement and an editor's stipend from American Society for Microbiology and Infectious Diseases Society of America and honoraria from the United States Medical Licensing Examination, UptoDate, and the Infectious Diseases Board Review Course.
Funding Information:
Grant Support: This work was supported by the Antimicrobial Resistance Leadership Group of the National Institutes of Health (award no. UM1 AI104681) and the Mayo Clinic Center for Individualized Medicine.
Publisher Copyright:
© 2016 Mayo Foundation for Medical Education and Research
PY - 2016/10/1
Y1 - 2016/10/1
N2 - There are a number of changes underway in modern clinical bacteriology laboratories. Panel-based molecular diagnostics are now available for numerous applications, including, but not limited to, detection of bacteria and select antibacterial resistance markers in positive blood culture bottles, detection of acute gastroenteritis pathogens in stool, and detection of selected causes of acute meningitis and encephalitis in the cerebrospinal fluid. Today, rapid point-of-care nucleic acid amplification tests are bringing the accuracy of sophisticated molecular diagnostics closer to patients. A proteomic technology, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, is enabling rapid, accurate, and cost-effective identification of bacteria, as well as fungi, recovered in cultures. Laboratory automation, common in chemistry laboratories, is now available for clinical bacteriology laboratories. Finally, there are several technologies under development, such as rapid phenotypic antimicrobial susceptibility testing, whole-genome sequencing, and metagenomic analysis for the detection of bacteria in clinical specimens. It is helpful for clinicians to be aware of the pace of new development in their bacteriology laboratory to enable appropriate test ordering, to enable test interpretation, and to work with their laboratories and antimicrobial stewardship programs to ensure that new technology is implemented to optimally improve patient care.
AB - There are a number of changes underway in modern clinical bacteriology laboratories. Panel-based molecular diagnostics are now available for numerous applications, including, but not limited to, detection of bacteria and select antibacterial resistance markers in positive blood culture bottles, detection of acute gastroenteritis pathogens in stool, and detection of selected causes of acute meningitis and encephalitis in the cerebrospinal fluid. Today, rapid point-of-care nucleic acid amplification tests are bringing the accuracy of sophisticated molecular diagnostics closer to patients. A proteomic technology, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, is enabling rapid, accurate, and cost-effective identification of bacteria, as well as fungi, recovered in cultures. Laboratory automation, common in chemistry laboratories, is now available for clinical bacteriology laboratories. Finally, there are several technologies under development, such as rapid phenotypic antimicrobial susceptibility testing, whole-genome sequencing, and metagenomic analysis for the detection of bacteria in clinical specimens. It is helpful for clinicians to be aware of the pace of new development in their bacteriology laboratory to enable appropriate test ordering, to enable test interpretation, and to work with their laboratories and antimicrobial stewardship programs to ensure that new technology is implemented to optimally improve patient care.
UR - http://www.scopus.com/inward/record.url?scp=84994234548&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994234548&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2016.06.020
DO - 10.1016/j.mayocp.2016.06.020
M3 - Review article
C2 - 27552910
AN - SCOPUS:84994234548
VL - 91
SP - 1448
EP - 1459
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
SN - 0025-6196
IS - 10
ER -